Therapeutic targeting of the PD-1/PD-L1 immune regulatory axis has led to meaningful results in the treatment of many solid tumors, including melanoma, renal cell carcinoma, NSCLC, and head & neck squamous cell carcinoma [7]. This evidence concerns the gene CD274 and melanoma.